What Everyone is Misreading in the Latest Post-Acute Policy Cycle

July 22, 2026  |  Post-Acute Care, Health Policy

Mike Rawaan, Founder and Managing Director

What the 2026–2027 CMS rules actually mean for home health, skilled nursing, inpatient rehab, and LTCHs — and how operators should respond The prevailing read on post-acute care right now goes something like this: rates are up, the staffing mandate is dead, and the big insurers are finally dismantling prior authorization. Relief has arrived.

That read is wrong on all three counts, and operators who build their 2027 plans on it will spend next year explaining variances to their boards. The real story of the past twelve months is a shift in where CMS applies pressure. The agency is loosening its grip on rates and staffing ratios while tightening it dramatically on enforcement, coding integrity, and program participation. Meanwhile, the most celebrated payer reform of the year — voluntary prior authorization reduction — explicitly skips the care settings that needed it most. Allow me correct the record.

The Rate Picture: A Good Year Followed by a Thinner One

Fiscal 2026 was, by recent standards, generous. Skilled nursing facilities received a 3.2% payment update worth roughly $1.16 billion. Inpatient rehabilitation facilities took a 2.6% increase. Home health agencies dodged a bullet when CMS scaled back a proposed $1.1 billion cut to roughly $220 million in the final CY 2026 rule — a retreat some read as the beginning of the end for the permanent-adjustment era under the Patient-Driven Groupings Model.

The FY 2027 proposals tell a different story. The proposed SNF rule offers a net 2.4% update — about $888 million — built on a 3.2% market basket minus a 0.8% productivity adjustment. IRFs fare best again, with a proposed net increase of 2.8%, or $355 million, and a meaningfully lower outlier threshold that adds an estimated $55 million in outlier payments. Long-term acute care hospitals get a proposed 2.4% update to the standard rate, but CMS proposes to hold the outlier threshold at its FY 2026 level — cold comfort for a sector whose defining reimbursement problem is absorbing enormous losses on its sickest patients before outlier payments trigger.

Home health is the most instructive case. The CY 2027 proposed rule, released July 1, carries a headline aggregate increase of 2.4%, or $420 million. Read past the headline. CMS also proposes a temporary 3.0% cut to the 30-day base rate to continue recouping what it estimates as $4.9 billion in cumulative PDGM overpayments through 2025 — this year's installment collects roughly $500 million, about a tenth of the balance. The agency declined to propose a new permanent cut, which is genuine progress. But the recoupment ledger remains open, and the temporary adjustments will keep coming.

One more pattern worth watching across all four settings: CMS is requesting information on setting-specific wage indexes for both SNFs and home health. Wage index reform is the sleeper issue of this rule cycle. Operators in markets where the hospital-based index has flattered their rates should start modeling the downside now.

And the rate updates increasingly come with strings. The SNF Value-Based Purchasing program doubles from four measures to eight in FY 2027 — adding discharge-to-community, falls with major injury, discharge function, and long-stay hospitalizations — with 2% of Part A payments (roughly $203 million) withheld and earned back on performance. Quality performance now moves real margin, not just Five-Star optics. And because the same measures determine TEAM network inclusion and Medicare Advantage network selection, operators who instrument them well get paid three times: through VBP, through plan networks, and through referral volume.

The Real Shift: From Rate Policy to Enforcement Policy

Here is what the crowd is missing. While everyone debates tenths of a percentage point on market baskets, CMS has quietly executed a strategic pivot toward program integrity — and the CY 2027 home health rule is its clearest expression. Though housed in a home health regulation, its provider enrollment provisions apply across every Medicare provider and supplier type. CMS proposes to make all enrollment revocations retroactive to the date of noncompliance, regardless of the revocation reason, and to expand the grounds for denial and revocation to include geographic fraud risk, certain misdemeanor convictions, and ownership-change noncompliance. CMS has also imposed a six-month nationwide moratorium on enrolling new home health agencies. The message is unambiguous: participation in Medicare is becoming a privilege the agency intends to police, not an entitlement it merely prices.

The same instinct shows up in payment policy. The FY 2027 SNF proposed rule includes a request for information on Patient-Driven Payment Model refinements aimed squarely at case-mix upcoding — following FY 2026's removal of 33 vague diagnoses from primary-diagnosis eligibility. An RFI is not a cut, but it is a warning shot, and operators whose PDPM capture strategies live near the line should treat it as one. And in traditional Medicare, the WISeR model launched in January across six states, introducing AI-powered prior authorization for 17 service categories the agency deems ripe for overutilization. Savor the irony: the same technology that triggered a Senate investigation when insurers used it against post-acute claims is now a CMS demonstration model.

Inpatient rehab is getting its own version of the treatment. The IRF Review Choice Demonstration — 100% pre-claim or post-payment review of Original Medicare admissions, with an 85% affirmation threshold to earn lighter-touch review — expanded from Alabama and Pennsylvania into Texas in March and California in May — the two largest IRF states. CMS has signaled intent to take the demonstration nationwide, which makes the RCD documentation standard the de facto national compliance bar today, wherever you operate. The CY 2027 rule also extends private equity and REIT ownership disclosure requirements to a broader range of provider types, taking the transparency regime that began with nursing homes sector-wide. The pattern across all of it - enrollment, coding, admissions review, ownership - is a single thesis: Medicare participation is becoming a continuously policed privilege.

Add the Transforming Episode Accountability Model - mandatory for roughly 750 hospitals as of January 1 - and the picture sharpens. TEAM puts hospitals at financial risk for 30-day post-surgical episodes, which means every post-acute provider in a TEAM market is now being evaluated, formally or informally, as a network partner. Referral relationships that ran on habit will increasingly run on data.

The Prior Authorization Head Fake

Now to the year's most celebrated reform. UnitedHealthcare has pledged to eliminate 30% of its remaining prior authorizations by the end of 2026. Humana eliminated roughly a third of its outpatient prior authorizations as of January 1. Both launched gold card programs and public metric reporting. The industry applauded.

Read the fine print. The named categories are outpatient surgeries, echocardiograms, colonoscopies, imaging, therapies, and chiropractic care. UnitedHealthcare's own published statistics on prior authorization reduction explicitly exclude transitions to post-acute care from the calculation. In other words, the reform everyone is celebrating carves out the single highest-friction, highest-denial category in the entire prior authorization universe; the hospital-to-post-acute transition.

And that category remains a problem, on the federal government's own evidence. The HHS Office of Inspector General (OIG) reported in June that Medicare Advantage organizations denied 12% of skilled nursing admission requests — and overturned 95% of those denials on appeal, a rate that speaks for itself about the quality of the initial determinations. Companion analysis found long-term care hospital denial rates of 71% to 80% at the three largest MA insurers, against 42% for the rest of the market. The relief that is actually reaching post-acute providers comes from regulators, not voluntary pledges: federal rules now require standard prior authorization decisions within seven calendar days and expedited decisions within 72 hours, with specific denial reasons and public reporting, and the bipartisan Medicare Advantage Improvement Act of 2026 takes direct aim at post-acute access. If you run a post-acute organization, your prior authorization strategy for 2027 should assume the voluntary reforms change nothing in your world.

The Payer Mix Undertow

Prior authorization is the visible symptom; payer mix is the disease. With Medicare Advantage past half of eligible beneficiaries, every point of penetration reshapes post-acute economics: plans pay below traditional Medicare, authorize shorter stays, and add administrative cost. The utilization effect is structural — research shows MA patients hospitalized for strokes and hip fractures are more likely to be discharged home rather than to a SNF compared with traditional Medicare patients, which means MA's growth mechanically suppresses facility volume even as the demographic wave builds up. And because most MA and managed Medicaid contracts are benchmarked to a percentage of the Medicare fee schedule, the thin FY 2027 updates compound: a 2.4% federal update will seem close to flat for an MA-heavy provider. A facility can post improving occupancy and declining revenue per bed in the same quarter. Operators tracking census without tracking payer mix are reading half the ledger.

The Medicaid side of the book carries its own unpriced risk. Most states now deliver long-term services and supports through managed care, and the One Big Beautiful Bill Act's (OBBBA) phased restrictions on provider taxes and state-directed payments — beginning in 2027–2028 — land directly on the mechanism states use to push supplemental dollars through MLTSS plans to nursing facilities. The law that gave the sector its staffing-mandate moratorium delivered its largest financing risk in the same statute. The strategic responses are maturing: payer-innovation contracting of the kind Enhabit Home Health & Hospice built to nearly 44% of non-Medicare visits, provider-owned institutional special needs plans that internalize the premium dollar, and disciplined exit from chronically underpaying contracts. Payer mix management will rival labor as the top strategic agenda item through 2027.

Staffing: The Mandate Died, the Shortage Didn't

HHS formally repealed the federal nursing home staffing mandate in December, following a court vacatur and a ten-year statutory moratorium. Operators cheered, understandably — the rule would have required on the order of 100,000 additional caregivers the labor market simply cannot supply. But the repeal solved a compliance problem, not a workforce problem. Average nursing hours per resident have fallen 7% since 2015. Immigrants make up roughly a quarter of the nursing home workforce and 41% of home care aides, and tightened immigration policy — terminated protected-status programs, a $100,000 H-1B fee — is stripping legally authorized workers out of buildings overnight. According to an Activated Insights Benchmarking Report, home care turnover still runs near 80%, and roughly 70% of new caregiver hires quit within their first 100 days.

The operators pulling away from the pack are treating workforce as a designed system rather than a recruiting problem: squeezing agency labor out of the mix and converting contract staff to permanent roles, building first-100-day onboarding programs with real structure, deploying virtual nursing to keep experienced clinicians in the workforce, and using AI documentation tools to return hours to the bedside. Deregulation bought the sector time. It did not buy a single additional caregiver.

Market Signals: Occupancy, Deals, and the Migration Home

The capital markets have already voted on this landscape. Senior housing and care occupancy has climbed for 19 consecutive quarters, reaching 89.5% in the first quarter, while new construction sits at its lowest level since 2012 — a supply-demand imbalance that structurally favors incumbents. Deal volume reflects it: the fourth quarter of 2025 set a record for announced skilled nursing transactions, the first quarter of 2026 delivered 231 deals worth more than $3.5 billion, and per-bed pricing holds near $95,000. The defining transaction of the cycle closed in May, when Kinderhook Industries completed its $1.1 billion take-private of Enhabit at roughly ten times estimated 2026 earnings — rational money paying for payer diversification, not fee-for-service froth. Meanwhile UnitedHealth's Amedisys acquisition made the nation's largest MA payer its largest home health operator, and Pennant Group built a multi-state platform out of the DOJ-mandated divestitures. Scale, payer diversification, and technology infrastructure now separate platforms from targets.

The care model itself is migrating in the same direction. Hospital-at-home — paying full inpatient rates for acute care delivered in the living room — keeps winning extensions, with House-passed legislation contemplating a run through 2030; every episode substitutes a facility-bound discharge with a home-based recovery served by home health and remote monitoring. RPM programs are producing readmission reductions large enough to anchor value-based contracts with MA plans, which bear readmission costs inside their capitated premiums. And AI has crossed from pilot to production where it touches revenue: documentation tools cutting MDS assessment time nearly in half, a national home health agency reducing claim denials 41%, and intake triage attacking a referral process in which nearly two-thirds of SNF referrals go unfilled. The common thread: capability that can be documented is becoming capital that can be monetized — with hospitals, payers, and acquirers alike.

What This Means for Operators ... and a Case in Point

Pull the threads together and the strategic picture looks like the automotive industry after the chip shortage. The winners were not the manufacturers who waited for supply to normalize; they were the ones who redesigned their supplier networks, secured the scarce inputs, and differentiated while competitors idled. Post-acute care is at the same inflection point. Rates will be adequate but unspectacular. Enforcement will intensify. MA friction will persist regardless of press releases. The scarce inputs are workforce, referral relationships, and operational credibility with payers and hospital partners. Every one of those is a design problem, which means every one of them rewards providers who implement policy changes deliberately, choose partners strategically, and build a differentiated position rather than a defensive one.

This is precisely the work we do at Covalence Health, and a recent engagement shows what it looks like in practice. A venture-backed startup building a home and durable medical equipment marketplace came to us with a sharp observation and a knowledge gap. The observation: discharge teams across hospitals, long-term care facilities, and home health providers lose days on HDME referrals because eligibility verification and prior authorization still run on fax machines, phone calls, and a patchwork of insurance portals. The gap: the company lacked the benefits-management, reimbursement, and competitive-landscape expertise to design a solution that would actually win.

We ran our three-phase business case methodology. Discovery came first — three weeks of in-person interviews, segmentation of the existing solution landscape, and competitive benchmarking across referral management. Business model prototyping followed, testing revenue and operating models against direct input from payers, health systems, competitors, and industry experts; that work validated capitation and administrative-services-only models as the strongest fits and surfaced the features buyers actually valued. The synthesis produced the key insight: plenty of companies had solved one or two pieces of the HDME ordering and fulfillment puzzle, but no one had a comprehensive solution across the entire process. And most importantly, no one had designed their solutions around the clinician and patient workflows.

Our recommendation was deliberately pragmatic. Rather than building everything from scratch, the client formed strategic partnerships with two complementary companies — one automating the provider referral process, the other curating health plan medical guidelines for eligibility and prior authorization — assembled into a modular solution that could be sold whole or decoupled, while the client kept full ownership of its core platform. The blueprint was delivered in late 2023; partnerships were finalized and the first customer closed by the second quarter of 2024 — six months from strategy to revenue. As the client's executive put it, our expertise kept them from investing in the wrong strategy. The full case study is available here.

The engagement is also newly timely. The CY 2027 proposed rule expands the DME benefit to certain external infusion pumps and home infusion drugs effective April 2027, clarifies face-to-face encounter requirements for DMEPOS replacements, and adds country-of-origin reporting to competitive bidding — a reminder that the HDME referral and fulfillment chain our client set out to fix is itself a moving regulatory target. Solutions built with the policy trajectory in view age well. Solutions built against a snapshot, not so much.

The Bottom Line

The post-acute care sector is not entering a period of relief. It is entering a period of selection. CMS is choosing which providers it trusts with program participation. Hospitals under the CMMI TEAM are choosing which post-acute partners earn their episodes. MA and managed Medicaid plans are choosing where friction stays high, where they can narrow networks, and which providers earn value-based terms. In a selection environment, the providers who win are the ones who read the rules earlier, implement faster, and pick partners with discipline — whether that partner is a referral platform, a technology vendor, or an advisor who has done this before.

Covalence Health helps post-acute providers, health plans, investors, and health technology companies do exactly that: translate policy into operating decisions, evaluate and select the right partners, and build differentiation that survives the next rule cycle. If the 2027 rules have you rethinking your position, we should talk.